ASTRON PULSAR STENT SYSTEM, PULSAR-18 STENT SYSTEM
Biotronik AG · Decision date Mar 23, 2017
What did the FDA approve?
FDA approved PMA P160025 for the Astron Pulsar Stent System and Pulsar-18 Stent System on March 23, 2017. The applicant is Biotronik AG, and the product code is NIP under the specialty Cardiovascular.
The stated indication is improving luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0mm and total lesion lengths up to 190mm. The source statement reports an intended purpose, not independent proof of safety or clinical effectiveness.
FDA approval order statement
Approval for the Astron Pulsar Stent System and Pulsar-18 Stent System. These devices are indicated for use to improve luminal diameter in patients with symptomatic de novo, restenotic or occlusive lesions located in the superficial femoral or proximal popliteal arteries, with reference vessel diameters from 3.0 to 6.0mm and total lesion lengths up to 190mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Mar 23, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160025
- Regulatory pathway
- Premarket approval application
- Applicant
- Biotronik AG
- Product code
- NIP
- Decision code
- APPR
- Decision date
- Mar 23, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Biotronik AG
- Product code
- NIP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160025 received
Application receipt date recorded by FDA.
P160025 · FDA decision
APPR
P160025/S026 · Related supplement
Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System
Timeline entries are records held by MedtechLedger for P160025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Abbott Vascular (Idef Technologies Inc) | PMA approval | Mar 28, 2014 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P160025
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



